Prognosis and pathological characteristics of five children with non-Shiga toxin-mediated hemolytic uremic syndrome

Pediatrics International

Volumn 49, Issue 2, 2007, Pages 196-201

  Kamioka, Ichiro ^a   Nozu, Kandai ^a   Fujita, Teruo ^a   Kaito, Hiroshi ^a   Tanaka, Ryojiro ^b   Yoshiya, Kunihiko ^c   Iijima, Kazumoto ^d   Nakanishi, Koichi ^e   Yoshikawa, Norishige ^e   Matsuo, Masafumi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Hyogo Children's Hospital   (Japan)

^c Hara Genitourinary Hospital   (Japan)

^d NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^e WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Campylobacter; Cortical necrosis; Non Shiga toxin mediated HUS; Poliomyelitis vaccine; Thrombotic microangiopathy

Indexed keywords

SHIGA TOXIN;

ADULT; ARTERY DISEASE; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; FEMALE; HEMOLYTIC UREMIC SYNDROME; HISTOLOGY; HUMAN; KIDNEY BIOPSY; KIDNEY CORTEX NECROSIS; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MEDICAL RECORD; PATHOLOGY; PEDIATRICS; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; CAMPYLOBACTER INFECTIONS; CHILD; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INFANT; KIDNEY; KIDNEY CORTEX NECROSIS; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; MALE; MICROCIRCULATION; PROGNOSIS; RECURRENCE; THROMBOSIS;

EID: 34147140549     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2007.02352.x     Document Type: Article

References (27)

1. Bitzan M, Bickford BB, Foster GH. Verotoxin (Shiga toxin) sensitizes renal epithelial cells to increased heme toxicity: Possible implications for the hemolytic uremic syndrome. J. Am. Soc. Nephrol. 2004; 15: 2334-43.
2. Siegler RL, Pavia AT, Hansen FL, Christofferson RD, Cook JB. Atypical hemolytic-uremic syndrome: A comparison with post-diarrheal disease. J. Pediatr. 1996; 128: 505-11.
3. Remuzzi G, Ruggenenti P. The hemolytic uremic syndrome. Kidney Int. 1995; 48: 2-19.
4. Pijpers AH, van Setten PA, van den Heuvel LP et al. Verocytotoxin-induced apoptosis of human microvascular endothelial cells. J. Am. Soc. Nephrol. 2001; 12: 767-78.
5. Taguchi T, Uchida H, Kiyokawa N et al. Verotoxins induce apoptosis in human renal tubular epithelium derived cells. Kidney Int. 1998; 53: 1681-8.
6. Filler G, Radhakrishnan S, Strain L, Hill A, Knoll G, Goodship TH. Challenges in the management of infantile factor H associated hemolytic uremic syndrome. Pediatr. Nephrol. 2004; 19: 908-11.
7. Fitzpatrick MM, Walters MD, Trompeter RS, Dillon MJ, Barratt TM. Atypical (non-diarrhea-associated) hemolytic-uremic syndrome in childhood. J. Pediatr. 1993; 122: 532-7.
8. Renaud C, Niaudet P, Gagnadoux MF, Broyer M, Habib R. Haemolytic uraemic syndrome: Prognostic factors in children over 3 years of age. Pediatr. Nephrol. 1995; 9: 24-9.
9. Flores FX, Jabs K, Thorne GM, Jaeger J, Linshaw MA, Somers MJ. Immune response to Escherichia coli O157: H7 in hemolytic uremic syndrome following salmonellosis. Pediatr. Nephrol. 1997; 11: 488-90.
10. Brandt J, Wong C, Mihm S et al. Invasive pneumococcal disease and hemolytic uremic syndrome. Pediatrics 2002; 110: 371-6.
11. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001; 60: 831-46.
12. Karim Y, Masood A. Haemolytic uraemic syndrome following mumps, measles, and rubella vaccination. Nephrol. Dial. Transplant. 2002; 17: 941-2.
13. Ault BH. Factor H and the pathogenesis of renal diseases. Pediatr. Nephrol. 2000; 14: 1045-53.
14. Kavanagh D, Kemp EJ, Mayland E et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 2005; 16: 2150-55.
15. Dragon-Durey MA, Fremeaux-Bacchi V. Atypical haemolytic uraemic syndrome and mutations in complement regulator genes. Springer Semin. Immunopathol. 2005; 27: 359-74.
16. Noris M, Brioschi S, Caprioli J et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003; 362: 1542-7.
17. Dragon-Durey MA, Loirat C, Cloarec S et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 2005; 16: 555-63.
18. Carter JE, Cimolai N. Hemolytic-uremic syndrome associated with acute Campylobacter upsaliensis gastroenteritis. Nephron 1996; 74: 489.
19. Sillero M, Almirall J. Campylobacter jejuni and hemolytic-uremic syndrome. Nephron 1999; 82: 363-4.
20. Parkhill J, Wren BW, Mungall K et al. The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences. Nature 2000; 403: 665-8.
21. De Jong MC, Monnens LA. Recurrent haemolytic uraemic syndrome. Padiatr. Padol. 1976; 11: 521-7.
22. Zipfel PF. Hemolytic uremic syndrome: How do factor H mutants mediate endothelial damage? Trends Immunol. 2001; 22: 345-8.
23. Sanchez-Corral P, Perez-Caballero D, Huarte O et al. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 2002; 71: 1285-95.
24. Argyle JC, Hogg RJ, Pysher TJ, Silva FG, Siegler RL. A clinico-pathological study of 24 children with hemolytic uremic syndrome. A report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol. 1990; 4: 52-8.
25. Habib R, Levy M, Gagnadoux MF, Broyer M. Prognosis of the hemolytic uremic syndrome in children. Adv. Nephrol. 1982; 11: 99-128.
26. D'Souza IE, Phadke KD, Subba Rao SD. Atypical hemolytic uremic syndrome. Indian Pediatr. 2002; 39: 162-7.
27. Nathanson S, Deschenes G. Prognosis of Streptococcus pneumoniae-induced hemolytic uremic syndrome. Pediatr. Nephrol. 2001; 16: 362-5.